SecBot SecBot
SECBOTREPLAY Home › Report › FATE

FATE · Fate Therapeutics presented early Phase 1 data for FT836, an…

Fate Therapeutics, Inc. · PRESS-RELEASE filed Jun 1, 2026 at 08:30 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 1, 2026 at 08:30 ET

Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid tumors, at ASCO 2026. In two heavily pre-treated KRASwt metastatic colorectal cancer patients, FT836 plus cetuximab without conditioning chemotherapy showed a 19% tumor reduction (Case 1) and a 52% liver lesion reduction (Case 2), with no DLTs, CRS, ICANS, or GvHD across nine patients. The data demonstrate first-in-human proof of trafficking and persistence in tumor tissue without lymphodepletion, but the sample is tiny (n=9 safety, n=5 efficacy-evaluable, n=2 with anti-tumor activity) and early-stage, limiting immediate stock-moving impact.

  • FT836 is an off-the-shelf, iPSC-derived CAR T-cell targeting MICA/B with Sword & Shield technology to eliminate need for conditioning chemotherapy.
  • Nine patients enrolled across two regimens (FT836 + cetuximab, n=6; FT836 + trastuzumab, n=3); no DLTs, CRS, ICANS, or GvHD observed.
  • Five patients available for efficacy; two KRASwt mCRC patients with 7 prior lines each showed tumor reduction: 19% sum-of-diameters (Case 1) and 52% liver lesion reduction (Case 2).
  • FT836 detected in peripheral blood (peak Day 4) and tumor tissue (Day 22 biopsy) without conditioning chemotherapy, with evidence of tumor immune microenvironment remodeling.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access